Browse IPO13

Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus.
Domain PF03810 Importin-beta N-terminal domain
PF08389 Exportin 1-like protein
Function

Functions in nuclear protein import as nuclear transport receptor. Serves as receptor for nuclear localization signals (NLS) in cargo substrates. Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus (By similarity). Mediates the nuclear import of UBC9, the RBM8A/MAGOH complex, PAX6 and probably other members of the paired homeobox family. Also mediates nuclear export of eIF-1A, and the cytoplasmic release of eIF-1A is triggered by the loading of import substrates onto IPO13.

> Gene Ontology
 
Biological Process GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0017038 protein import
GO:0034504 protein localization to nucleus
GO:0044744 protein targeting to nucleus
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:1902593 single-organism nuclear import
Molecular Function GO:0005048 signal sequence binding
GO:0008139 nuclear localization sequence binding
GO:0008536 Ran GTPase binding
GO:0008565 protein transporter activity
GO:0017016 Ras GTPase binding
GO:0031267 small GTPase binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0051020 GTPase binding
Cellular Component GO:0005635 nuclear envelope
GO:0031965 nuclear membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IPO13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IPO13 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.24; FDR: 0.029500 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IPO13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0710.798
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2630.89
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0660.961
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0370.893
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0550.976
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1540.947
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0120.971
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.080.957
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0480.977
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0550.967
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3410.858
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0460.449
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IPO13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IPO13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IPO13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IPO13.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IPO13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IPO13 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IPO13 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIPO13
Nameimportin 13
Aliases IMP13; KIAA0724; RANBP13; KAP13; Ran binding protein 13; karyopherin 13; karyopherin-13; late gestation lung ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IPO13 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.